NWPF

News ArchivesRead News

Medication Alone Insufficient in Treating Depression in Parkinson's Disease

Tuesday June 25, 2013

National Parkinson Foundation

Sacramento Bee - New findings from the National Parkinson Foundation (NPF) Parkinson's Outcomes Project show that antidepressants alone do not improve depression in Parkinson's disease. Depression was most effectively treated at centers that refer their depressed patients to a mental health professional or social worker. These findings were presented last week during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013.

In the study, "Approach to Treatment of Depression in Parkinson's Disease," Peter Schmidt, Ph.D., and colleagues examined which approaches to depression care correlated with the lowest prevalence of depression among patients seen at NPF's Centers of Excellence. Patients were treated with antidepressant medications, counseling by a social worker, treatment by a mental health professional, or a combination.

"This work is part of the larger NPF mission: to determine what works best in the treatment and care of Parkinson's with an aim toward slowing the impact of the disease," said Peter Schmidt, Ph.D., lead author of the study and Vice President, Programs at NPF. "This particular study highlights the importance of team care, something NPF has long advocated at its Centers of Excellence. We found the best care is achieved when neurologists coordinate with other health professionals to aggressively fight Parkinson's. In fact, a 'depression team,' consisting of a social worker and a psychiatrist coordinating with the neurologist, yielded the best results."

The study, analyzing 2,423 patients at 10 NPF Centers of Excellence found 1,121 depressed patients (46%), but at the best center only 30% showed signs of depression. Centers prescribed antidepressant medications to between 29% and 63% of their depressed patients, but high-prescribing centers achieved no significant reduction in depression versus low-prescribing centers. Other treatments, however, did correlate with better outcomes.

This work is part of the Parkinson's Outcomes Project, a longitudinal look at which treatments produce the best health outcomes. Started in 2009, the study represents data from more than 6,000 people with Parkinson's disease in four countries.

Recent News

Jul 24 - Parkinson's: Mutant gene interaction may pave the way for new treatments
Jul 22 - Boxing training used to fight against Parkinson's disease
Jul 17 - Stem cell treatment breakthrough could cure Parkinson’s patients
Jul 14 - Cancer drug shows early promise for Parkinson's disease
Jul 13 - Opinion: Dividing the Caregiving Responsibilities Between Siblings
Jul 12 - Researchers make advance in possible treatments for Gaucher, Parkinson’s diseases
Jul 11 - Parkinson’s Head Trauma Link Looks Even Stronger
Jul 7 - Penn students’ start-up XEED puts wearables to work against Parkinson’s disease
Jul 5 - Last Patient Enrolled in Pivotal Phase 3 Parkinson’s Disease Trial, Cynapsus Therapeutics Says
Jun 29 - Exoskeleton Could Quell the Tremors of Parkinson's Disease Patients at Crucial Moments
Jun 28 - Parkinson's disease: New protein discovery could fuel new treatments
Jun 27 - Study finds direct evidence linking Parkinson’s to autoimmune disease; 2 genes that are key regulators of immune system discovered
Jun 27 - Blocking key enzyme halts parkinson's disease symptoms in mice
Jun 23 - Parkinson's Research Might Benefit from Novel Discovery of Zinc Transport Protein Structure
Jun 23 - Parkinson's disease breakthrough 'could lead to cure'
Jun 20 - More American men diagnosed with Parkinson's
Jun 15 - First monkey genetically engineered to have Parkinson’s created
Jun 14 - Fighting Parkinson's in the lab
Jun 9 - A New Gene Has Been Linked to Parkinson's Disease
Jun 6 - A neurologist weighs in on Muhammad Ali's battle with Parkinson's disease